DK1856085T3 - Flavonoidforbindelser og anvendelser deraf - Google Patents

Flavonoidforbindelser og anvendelser deraf Download PDF

Info

Publication number
DK1856085T3
DK1856085T3 DK06704987.4T DK06704987T DK1856085T3 DK 1856085 T3 DK1856085 T3 DK 1856085T3 DK 06704987 T DK06704987 T DK 06704987T DK 1856085 T3 DK1856085 T3 DK 1856085T3
Authority
DK
Denmark
Prior art keywords
compound
flavone
hemiadipate
compound according
diohf3ha
Prior art date
Application number
DK06704987.4T
Other languages
English (en)
Inventor
Gregory James Dusting
Owen Llewellyn Woodman
Clive Newton May
Bevyn Jarrott
Original Assignee
Howard Florey Inst Pty Ltd
Armaron Bio Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2005901214A external-priority patent/AU2005901214A0/en
Application filed by Howard Florey Inst Pty Ltd, Armaron Bio Pty Ltd filed Critical Howard Florey Inst Pty Ltd
Application granted granted Critical
Publication of DK1856085T3 publication Critical patent/DK1856085T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
    • C07D311/26—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3
    • C07D311/28—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only
    • C07D311/30—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only not hydrogenated in the hetero ring, e.g. flavones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
    • C07D311/26—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3
    • C07D311/28—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only
    • C07D311/32—2,3-Dihydro derivatives, e.g. flavanones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/655—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
    • C07F9/6552—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a six-membered ring
    • C07F9/65522—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a six-membered ring condensed with carbocyclic rings or carbocyclic ring systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Pyrane Compounds (AREA)

Claims (22)

1. Forbindelse med den generelle formel I:
hvor: — betegner en enkelt eller dobbelt binding; og (i) R1, R2, R3, R4, R5 er uafhængigt valgt fra H, OH eller en gruppe ifølge formel (la):
(la) hvor: O er oxygen; L og D er manglende og E er en ester ifølge formlen (Ic):
(Ic) hvor Q er en ikke-substitueret lineær eller forgrenet kæde alkylen med 1 til 6 kulstofatomer; W er O; og X er H, substitueret eller ikke-substitueret alkyl, et mono-kationisk salt, eller et ammonium kationisk salt; og forudsat at mindst et af R1, R2, R3, R4, R5 er andet end H eller OH; eller dets farmaceutisk acceptable salt.
2. Forbindelse ifølge krav 1, hvor R4 og R5 begge er H.
3. Forbindelse ifølge krav 2, hvor R1 og R2 begge er OH.
4. Forbindelse ifølge krav 1, hvor hvert af R1, R2 og R4 er H.
5. Forbindelse ifølge krav 3, hvor — betegner en dobbelt binding, Q er (CH2)n, hvor n er et heltal fra 2 til 6 og X er H.
6. Forbindelse ifølge krav 5, hvor n er 4.
7. Forbindelse ifølge krav 1 valgt fra gruppen omfattende 3-(benzyloxycarbonylbutylcarbonyloxy)flavon; 3-hydroxyflavon 3-hemiadipat; 4'-(benzyloxy)-3-(benzyloxycarbonylbutylcarbonyloxy)flavon; 4'-hydroxyflavon 3-hemiadipat; 3',4'-dibenzyloxy-3-(benzyloxycarbonylbutylcarbonyloxy)flavon; 3',4'-dihydroxyflavon 3-hemiadipat; 3,4'-di- (benzyloxycarbonylbutylcarbonyloxy)flavon; flavon 3,4'-bis(hemiadipat); 3,7-di-(benzyloxycarbonylbutylcarbonyloxy)flavon; 3,7-dihydroxyflavon 3,7-bis(hemiadipat); eller 4'-dydroxy-3-dydroxyflavon-3-kvarternær ammoniumester.
8. Forbindelse omfattende en farmaceutisk og/eller veterinær acceptabel bærer eller fortynder sammen med mindst en forbindelse ifølge et hvilket som helst af de foregående krav.
9. Forbindelse ifølge et hvilket som helst af kravene 1 til 7 til anvendelse i forebyggelse og/eller behandling af en eller flere sygdomme hos et individ associeret med tilstedeværelsen af reaktive ilt arter (ROS).
10. Forbindelse ifølge krav 9, hvor individet som har brug for sådan behandling har risiko for at udvikle iskæmi.
11. Forbindelse ifølge krav 9, hvor individet lider af iskæmi og/eller reperfusionsskade som resultat afen akut eller kronisk tilstand.
12. Forbindelse ifølge krav 11, hvor den kroniske tilstand er valgt fra cancer, cerebrovaskulær sygdom, lungekarsygdom, aterosklerose, arteriesygdom, kongestiv hjertesygdom, hjerteinfarktsygdom, periferkarsygdom, diabetes, hypertension, migræne, brandsår, kronisk obstruktiv lungesygdom og retinalkarsygdom.
13. Forbindelse ifølge krav 12, hvor den akutte tilstand er valgt fra slagtilfælde, myokardieinfarkt, mekanisk traume som resultat af knusningslæsion eller kirurgi.
14. Forbindelse ifølge krav 13, hvor kirurgien er karkirurgi.
15. Forbindelse ifølge krav 14, hvor karkirurgien er hjerte-bypass og/eller transplantationskirurgi.
16. Forbindelse ifølge et hvilket som helst af kravene 1 til 7 til anvendelse i forebyggelse af, forsinke påbegyndelsen af og/eller nedsætte udviklingen af aterosklerose og/eller hjertekarsygdom hos et individ.
17. Forbindelse ifølge et hvilket som helst af kravene 1 til 7 til anvendelse i forebyggelse af og/eller mindst forbedre skaden hos et individ forårsaget af iskæmi og/eller reperfusionskade.
18. Forbindelse ifølge et hvilket som helst af kravene 1 til 7 til anvendelse i forebyggelse og/eller mindst forbedre skaden hos et individ forårsaget af administrationen af et terapeutisk middel.
19. Forbindelse ifølge krav 18, hvor det terapeutiske middel er et oxidativt terapeutisk middel.
20. Forbindelse ifølge krav 18, hvor det terapeutiske middel er et anticancermiddel.
21. Forbindelse ifølge krav 20, hvor anticancermidlet er anthracyclin og homologer deraf.
22. Forbindelse ifølge et hvilket som helst af kravene 9 til 21, hvor forbindelsen er administreret til individet oralt.
DK06704987.4T 2005-03-11 2006-03-10 Flavonoidforbindelser og anvendelser deraf DK1856085T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2005901214A AU2005901214A0 (en) 2005-03-11 Flavonoid compounds and uses thereof
PCT/AU2006/000314 WO2006094357A1 (en) 2005-03-11 2006-03-10 Flavonoid compounds and uses thereof

Publications (1)

Publication Number Publication Date
DK1856085T3 true DK1856085T3 (da) 2015-10-05

Family

ID=36952879

Family Applications (1)

Application Number Title Priority Date Filing Date
DK06704987.4T DK1856085T3 (da) 2005-03-11 2006-03-10 Flavonoidforbindelser og anvendelser deraf

Country Status (15)

Country Link
US (1) US8017649B2 (da)
EP (1) EP1856085B1 (da)
JP (1) JP5380069B2 (da)
KR (1) KR101397510B1 (da)
CN (1) CN101137639B (da)
AU (1) AU2006222556B2 (da)
BR (1) BRPI0608402B8 (da)
CA (1) CA2601028C (da)
DK (1) DK1856085T3 (da)
ES (1) ES2552108T3 (da)
NZ (1) NZ560633A (da)
RU (1) RU2431634C2 (da)
SG (1) SG162773A1 (da)
WO (1) WO2006094357A1 (da)
ZA (1) ZA200707427B (da)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8017649B2 (en) 2005-03-11 2011-09-13 Howard Florey Institute Of Experimental Physiology And Medicine Flavonoid compounds and uses thereof
AU2006233256B2 (en) * 2006-10-30 2012-01-19 Armaron Bio Pty Ltd Improved flavonols
CA2673863A1 (en) * 2006-12-28 2008-07-10 Limerick Biopharma, Inc. Methods and compositions for therapeutic treatment
KR100930467B1 (ko) * 2007-06-07 2009-12-08 동아제약주식회사 점액분비를 촉진시키는 3',4',5-트리메톡시 플라본 유도체화합물, 그의 제조방법 및 약학적 용도
US20090082400A1 (en) * 2007-07-31 2009-03-26 Ving Lee Soluble pyrone analogs methods and compositions
WO2009018350A1 (en) * 2007-07-31 2009-02-05 Limerick Biopharma, Inc. Pyrone analog compositions and methods
JP2011500512A (ja) 2007-07-31 2011-01-06 リメリック バイオファーマ，インコーポレイティド リン酸化ピロン類似体および方法
US8034838B2 (en) * 2008-05-29 2011-10-11 Daryl Lee Thompson Composition and method for the treatment of neurological disorders
CN102438614A (zh) * 2008-10-10 2012-05-02 利默里克生物制药公司 用于治疗的吡喃酮类似物
KR101586992B1 (ko) * 2009-03-20 2016-01-20 건국대학교 산학협력단 플라보노이드를 유효성분으로 하는 배아 발생 개선용 조성물 및 그 방법
WO2011013735A1 (ja) * 2009-07-31 2011-02-03 国立大学法人 岡山大学 新規フラバノン誘導体
AU2011282776B2 (en) * 2010-07-27 2014-06-12 Boston Medical Center Corporation Aryl hydrocarbon receptor (AhR) modifiers as novel cancer therapeutics
CN102464642B (zh) * 2010-11-18 2014-04-23 谢联金 一种化合物及其制备方法及其作为饲料添加剂的应用
KR101459712B1 (ko) * 2012-09-10 2014-11-12 건국대학교 산학협력단 야누스 키나아제 3을 활성을 선택적으로 저해하는 플라보노이드 유도체
MX368855B (es) * 2012-10-11 2019-10-18 Armaron Bio Pty Ltd Compuestos de flavonoides novedosos y sus usos.
CN102861053B (zh) * 2012-10-27 2013-07-10 南京大学 Houttuynoid D在治疗白血病药物中的应用
CN104592246A (zh) * 2013-10-30 2015-05-06 周亚伟 一种黄酮类化合物及其制备方法和应用
US9260461B2 (en) * 2014-02-03 2016-02-16 Versitech Limited Water-soluble derivatives and prodrugs of acacetin and methods of making and using thereof
CN106659701B (zh) * 2014-06-30 2021-04-27 加尼福尼亚大学董事会 用于治疗年龄相关性症状和疾病的酮基丁酸酯化合物和组合物
CN104387360B (zh) * 2014-11-21 2016-10-05 潍坊医学院 柚皮素脂肪酸酯、其制备方法和以该化合物为活性成分的药物组合物及其应用
US10123991B2 (en) 2015-05-15 2018-11-13 Global Biolife Inc. Electrophilically enhanced phenolic compounds for treating inflammatory related diseases and disorders
CN105153093B (zh) * 2015-08-29 2017-07-21 西南民族大学 一种黄酮类化合物及其制备方法和用途
CN105153254B (zh) * 2015-08-29 2018-03-30 西南民族大学 一种黄酮类化合物
CN106632479B (zh) * 2016-12-22 2018-10-23 贵州大学 O,o’-二烷基-o”-(取代黄酮-3-基)磷酸酯类衍生物、制备方法及应用
WO2019005829A1 (en) * 2017-06-26 2019-01-03 Wayne State University METHODS AND COMPOSITIONS RELATING TO CANCER DEPENDENT ON HORMONE RECEPTORS
CN107382941B (zh) * 2017-07-10 2020-05-08 石家庄学院 黄酮衍生物及其制备方法和应用
CN111225561A (zh) * 2017-07-18 2020-06-02 Pvac医药科技有限公司 抗细菌物质及其组合物、使用其的医学和非医学用途以及包含所述物质和组合物的产物
CN109280067B (zh) * 2017-07-21 2022-07-05 南京正大天晴制药有限公司 香叶木苷衍生物、其制备方法以及医药用途
CN107550902A (zh) * 2017-10-31 2018-01-09 上海华堇生物技术有限责任公司 黄颜木素的药物用途
CN108752378A (zh) * 2018-07-12 2018-11-06 四川福思达生物技术开发有限责任公司 一种甲基次磷酸单烷基酯的合成方法
CN108997426B (zh) * 2018-07-19 2020-11-13 大连理工大学 靶向Hsp60的黄酮烷氧基氨基磷酸酯衍生物、制备及应用
CN114656579A (zh) * 2020-12-22 2022-06-24 安庆北化大科技园有限公司 一种低毒的黄酮醇磺酸酯类光引发剂及可见光引发体系和应用
CN113045527B (zh) * 2021-03-22 2022-11-08 广东省科学院动物研究所 二氢色原酮衍生物及其合成方法和用途
CN113321633B (zh) * 2021-05-21 2022-03-15 湖北工业大学 槲皮素-3-o-乙酸-(3-氯-4-硫代氨基)-苯酯及在制备糖尿病药物中的应用
CN115504970B (zh) * 2022-10-18 2023-04-18 黑龙江中医药大学 一种用于治疗心肌缺血的黄酮类衍生物及其制备方法
CN116102596B (zh) * 2022-12-13 2026-03-10 黑龙江八一农垦大学 灯盏乙素苷元7位磷酸酯类衍生物及其制备方法及用途
CN119504681B (zh) * 2024-11-27 2025-11-18 河南中烟工业有限责任公司 一种降焦减刺潜香化合物、制备方法、应用及应用方法

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US650846A (en) * 1899-05-10 1900-06-05 Heiman H Levy Branding-machine.
US3509026A (en) * 1967-01-19 1970-04-28 Litton Systems Inc Method of and apparatus for indicating the sensitivity of microorganisms to antibiotics
GB1461777A (en) * 1973-06-08 1977-01-19 Fisons Ltd 2-phenyl-4-oxo-4h-1-benzopyran derivatives
CA1309672C (en) 1983-01-27 1992-11-03 Jannis G. Stavrianopoulos Methods and structures employing non-radioactive chemically-labeled polynucleotide probes
DE3442639A1 (de) * 1984-11-22 1986-05-22 Dr. Madaus & Co, 5000 Köln Flavolignanderivate, verfahren zu deren herstellung und arzneimittel, die diese verbindungen enthalten
US5070018A (en) * 1986-11-07 1991-12-03 The Board Of Trustees Of The Leland Stanford Junior University Method of controlling gene expression
JPH01153695A (ja) * 1987-12-11 1989-06-15 Showa Denko Kk ルチンまたはケルセチンリン酸エステルの製造法
JPH01308476A (ja) * 1988-06-06 1989-12-13 Showa Denko Kk 紫外線吸収剤
GB8926715D0 (en) * 1989-11-28 1990-01-17 Haessle Ab Improvements relating to the administration of pharmaceutical agents
DE4134384A1 (de) * 1991-10-17 1993-04-22 Ruetgerswerke Ag Modifizierte huminate, verfahren zu ihrer herstellung und verwendung
IT1254469B (it) * 1992-02-25 1995-09-25 Recordati Chem Pharm Derivati benzopiranici e benzotiopiranici
IL112764A0 (en) * 1994-03-18 1995-05-26 Ferrer Int New chromene derivatives
FR2719467B1 (fr) * 1994-05-05 1996-05-31 Oreal Utilisation de flavonoïdes pour préserver et/ou renforcer les propriétés mécaniques des cheveux et procédé de protection des cheveux utilisant ces composés.
AU4515996A (en) * 1995-01-09 1996-07-31 Alpha-Therapeutics, Inc. Methods for increasing the bioavailability of biological active agents
US6506792B1 (en) * 1997-03-04 2003-01-14 Sterix Limited Compounds that inhibit oestrone sulphatase and/or aromatase and methods for making and using
US6921776B1 (en) * 1996-02-16 2005-07-26 Sterix Limited Compound
FR2764889B1 (fr) 1997-06-20 2000-09-01 Sod Conseils Rech Applic Nouveaux derives du 2-(iminomethyl)amino-phenyle, leur preparation, leur application a titre de medicaments et les compositions pharmaceutiques les contenant
US6180661B1 (en) * 1997-04-28 2001-01-30 Marigen, S.A. Bioflavonol-glycoside peresters and their incorporation into pharmacologically active concentrates and ultramicroemulsions
US5972995A (en) * 1997-10-16 1999-10-26 Children's Hospital Medical Center Of Northern California Compositions and methods for cystic fibrosis therapy
FR2778663B1 (fr) * 1998-05-15 2001-05-18 Coletica Nouveaux esters de flavonoides,leur utilisation en cosmetique, dermopharmacie, en pharmacie et en agro-alimentaire
ES2263213T3 (es) * 1998-06-18 2006-12-01 Consiglio Nazionale Delle Ricerche Procedimiento biocatalitico para la preparacion de 3-acil flavonoides.
JP2002523501A (ja) 1998-09-01 2002-07-30 エルジ ケミカル リミテッド フラボン構造を有する新規なｃｄｋ阻害剤
WO2000023073A1 (en) * 1998-10-20 2000-04-27 Korea Institute Of Science And Technology Bioflavonoids as plasma high density lipoprotein level increasing agent
CA2358967A1 (en) * 1999-01-27 2000-08-03 Zielinski Laboratory Hesperitin pro-forms with enhanced bioavailability
EP1055408A1 (de) * 1999-05-26 2000-11-29 Nutrinova Nutrition Specialties & Food Ingredients GmbH Sorbatkonservierte Mittel, Verfahren zu deren Herstellung und ihre Verwendung
US6555523B1 (en) * 1999-07-08 2003-04-29 Patrick T. Prendergast Use of cirsiliol and derivatives to treat infections
EP1214308A2 (en) * 1999-09-23 2002-06-19 Vereniging Voor Christelijk Wetenschappelijk Onderwijs Novel flavonoids
DE10003786A1 (de) * 2000-01-28 2001-08-02 Merck Patent Gmbh Galenische Formulierung
EP1127572A3 (en) * 2000-02-25 2003-05-02 Basf Aktiengesellschaft Use of flavones for treating cycloxygenase-2 mediated diseases
GB2348371B (en) * 2000-03-14 2001-04-04 Soares Da Silva Patricio Compositions comprising blockers of L-DOPA renal cell transfer for the treatment of Parkinson's disease
EP1136073A1 (en) * 2000-03-22 2001-09-26 N.V. Nutricia Compositions suitable for the treatment of damage caused by ischemia/reperfusion or oxidative stress
AU778128B2 (en) * 2000-04-19 2004-11-18 Nof Corporation Cosmetic composition
DE10031457C2 (de) * 2000-06-28 2002-12-12 Jean Krutmann Verwendung von O-beta-Hydroxyethylrutosid oder dessen Aglycon zur systemischen Behandlung und Prophylaxe von UV-induzierten Dermatosen und unerwünschten Langzeitfolgen von UV-Bestrahlungen
AU2001279587B2 (en) * 2000-07-28 2006-08-17 Immupharm Aps Method of treating symptoms of common cold, allergic rhinitis and infections relating to the respiratory tract
DE10056400A1 (de) * 2000-11-14 2002-05-23 Merck Patent Gmbh Galenische Formulierung
FR2820974B1 (fr) * 2001-02-21 2004-02-13 Pharmascience Lab Composition topique comprenant une solution vraie contenant un derive de chromane ou de chromene, son procede de preparation et son utilisation cosmetique et therapeutique
JP3691764B2 (ja) * 2001-03-07 2005-09-07 オリンパス株式会社 オートクレーブ装置
WO2004001058A2 (en) * 2001-05-04 2003-12-31 Paratek Pharmaceuticals, Inc. Transcription factor modulating compounds and methods of use thereof
UY26816A1 (es) * 2001-07-04 2003-04-30 Horacio Heinzen Una preparación liposomal de achyrocline satureioides ("marcela"), flavonoides y derivados semisintéticos, para la protección del tejido cerebral frente al dano isquémico- vascular y neurodegenerativo.
FI20011507A0 (fi) 2001-07-10 2001-07-10 Orion Corp Uusia yhdisteitä
MXPA04002077A (es) * 2001-09-06 2005-02-17 Synorx Inc Inhibicion por 3-doxiflavonoides de actividad de t-linfocitos y terapias relacionadas.
ITRM20010600A1 (it) * 2001-10-04 2003-04-04 Brane Tech S R L Composti flavonoidici capaci di modificare lo stato fisico e/o dinamico di membrane biologiche e di stimolare la sintesi endogena di protein
GB0125532D0 (en) * 2001-10-24 2001-12-12 Burton Michael Enzyme activity indicators
US20030125264A1 (en) * 2001-12-29 2003-07-03 Kimberly-Clark Worldwide, Inc. Methods For Treating Wounds
US20050032882A1 (en) * 2002-03-06 2005-02-10 Sophie Chen Botanical extract compositions and methods of use
US8945518B2 (en) * 2002-04-30 2015-02-03 Unigen, Inc. Formulation of dual eicosanoid system and cytokine system inhibitors for use in the prevention and treatment of oral diseases and conditions
KR100946822B1 (ko) * 2002-05-01 2010-03-09 가부시끼가이샤 하야시바라 세이부쓰 가가꾸 겐꾸조 칼슘 함유 조직 강화제 및 그 용도
FR2841784B1 (fr) 2002-07-08 2007-03-02 Composition a base de derives de 1,3-diphenylprop-2en-1-one substitues, preparation et utilisations
US20050080024A1 (en) * 2002-08-15 2005-04-14 Joseph Tucker Nitric oxide donating derivatives for the treatment of cardiovascular disorders
US20050080021A1 (en) * 2002-08-15 2005-04-14 Joseph Tucker Nitric oxide donating derivatives of stilbenes, polyphenols and flavonoids for the treatment of cardiovascular disorders
DE10244282A1 (de) * 2002-09-23 2004-04-01 Merck Patent Gmbh Zubereitung mit antioxidanten Eigenschaften
AU2003263162B2 (en) * 2002-10-24 2009-05-07 Immupharm A/S Pharmaceutical compositions comprising flavonoids and menthol
US20060135445A1 (en) * 2003-02-04 2006-06-22 Kabushiki Kaisha Yakult Honsha Breast cancer-resistant protein inhibitor
US20050079235A1 (en) * 2003-10-09 2005-04-14 Eggert Stockfleth Use of a polyphenol for the treatment of actinic keratosis
US7910138B2 (en) * 2003-10-09 2011-03-22 Medigene Ag Use of a polyphenol for the treatment of a cancerous or precancerous lesion of the skin
JP2007509035A (ja) * 2003-10-10 2007-04-12 レスバーロジックス コーポレイション Ｅｇｒ−１エンハンサー要素に関連する疾患の処置
CN101001670B (zh) * 2004-05-18 2012-10-03 澳美制药厂有限公司 用于睡眠障碍的组合物
US20060014705A1 (en) * 2004-06-30 2006-01-19 Howitz Konrad T Compositions and methods for selectively activating human sirtuins
US20060105967A1 (en) * 2004-11-18 2006-05-18 Advanced Gene Technology, Corp. Flavone derivatives as TNFalpha inhibitors or antagonists
US8017649B2 (en) 2005-03-11 2011-09-13 Howard Florey Institute Of Experimental Physiology And Medicine Flavonoid compounds and uses thereof
TWI282276B (en) * 2005-04-12 2007-06-11 Univ Taipei Medical Pharmaceutical composition containing flavonoids which possess selective inhibition on phosphodiesterase 4 or 3/4
US20070037193A1 (en) * 2005-08-12 2007-02-15 Rong-Hwa Lin Modulation of peroxisome proliferator-activated receptors
WO2007082178A2 (en) 2006-01-06 2007-07-19 Abgenomics Corporation Prostaglandin reductase inhibitors

Also Published As

Publication number Publication date
CN101137639B (zh) 2012-05-23
BRPI0608402B8 (pt) 2021-05-25
US20090130051A1 (en) 2009-05-21
RU2431634C2 (ru) 2011-10-20
NZ560633A (en) 2011-08-26
RU2007137659A (ru) 2009-04-20
CA2601028A1 (en) 2006-09-14
CN101137639A (zh) 2008-03-05
SG162773A1 (en) 2010-07-29
JP5380069B2 (ja) 2014-01-08
EP1856085A1 (en) 2007-11-21
KR101397510B1 (ko) 2014-05-22
AU2006222556B2 (en) 2011-09-29
US8017649B2 (en) 2011-09-13
JP2008532951A (ja) 2008-08-21
ZA200707427B (en) 2008-11-26
AU2006222556A1 (en) 2006-09-14
BRPI0608402A2 (pt) 2009-12-29
WO2006094357A1 (en) 2006-09-14
KR20070114315A (ko) 2007-11-30
EP1856085B1 (en) 2015-07-08
CA2601028C (en) 2014-05-27
BRPI0608402B1 (pt) 2020-10-13
ES2552108T3 (es) 2015-11-25
EP1856085A4 (en) 2010-11-03

Similar Documents

Publication Publication Date Title
DK1856085T3 (da) Flavonoidforbindelser og anvendelser deraf
EP0765160B1 (en) Dexanabinol derivatives and their use as neuroprotective pharmaceutical compositions
EP2720693A1 (en) Chromane-like cyclic prenylflavonoids for the medical intervention in neurological disorders
PL207707B1 (pl) Kompozycja do leczenia lub zapobiegania stanom patologicznym związanym ze stanami zapalnymi, neurodegeneracją, deregulacją metabolizmu lipidów i/lub glukozy, rozrostem komórek i/lub różnicowaniem komórek i/lub ze starzeniem się skóry lub ośrodkowego układu nerwowego
KR100526119B1 (ko) 테트라졸을 포함하는 이차아민으로 치환된 벤조피란 유도체
JP2018184414A (ja) 新規フラボノイド化合物およびその使用
US9029419B2 (en) Use of zinc N-acetyltaurinate
CN108904481A (zh) 邻羟基查尔酮类似物在制备抗氧化药物中的应用
US12195437B2 (en) Lipophenolic flavonoid derivatives useful to reduce carbonyl and oxidative stresses (COS)
KR100454649B1 (ko) 니트론 함유 셀레노 화합물, 이의 제조방법 및 치료적 용도